phase readout
savePhase 2 primary completion: Local and Systemic Immune Modulation by Rilvegostomig (AZD2936) in the Treatment of Advanced Gastric Cancer (RILVE Project)
June 1, 2030updated 28d ago
community read0 votes
Sponsor: Vall d'Hebron Institute of Oncology. Status: Not yet recruiting. Conditions: Advanced Gastric Cancer. NCT07788664.
view source ↗Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that